King's College London

Research portal

Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience

Research output: Contribution to journalArticle

Joana Desterro, Donal P. McLornan, Natalia Curto Garcia, Jennifer O'Sullivan, Samah Alimam, Clodagh Keohane, Claire Woodley, Yvonne Francis, Shahram Kordasti, Deepti H. Radia, Claire N. Harrison

Original languageEnglish
Pages (from-to)561-564
Number of pages4
JournalBritish Journal of Haematology
Volume186
Issue number4
Early online date15 May 2019
DOIs
Publication statusE-pub ahead of print - 15 May 2019

King's Authors

Abstract

Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the ‘real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454